HLVX (HilleVax) Cash And Cash Equivalents : $47.49 Mil (As of Mar. 2025)

View and export this data going back to 2022. Start your Free Trial

What is HilleVax Cash And Cash Equivalents?

HilleVax's quarterly cash and cash equivalents increased from Sep. 2024 ($103.76 Mil) to Dec. 2024 ($154.47 Mil) but then stayed the same from Dec. 2024 ($154.47 Mil) to Mar. 2025 ($47.49 Mil).

HilleVax's annual cash and cash equivalents declined from Dec. 2022 ($279.40 Mil) to Dec. 2023 ($216.68 Mil) and declined from Dec. 2023 ($216.68 Mil) to Dec. 2024 ($154.47 Mil).

HilleVax Cash And Cash Equivalents Historical Data

The historical data trend for HilleVax's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HilleVax Cash And Cash Equivalents Chart

HilleVax Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Cash And Cash Equivalents

0.46

124.57

279.40

216.68

154.47

HilleVax Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Cash And Cash Equivalents	Get a 7-Day Free Trial													141.08	108.44	103.76	154.47	47.49

HilleVax Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

HilleVax (NAS:HLVX) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

HilleVax Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of HilleVax's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

HilleVax Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HilleVax Inc (NAS:HLVX) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

321 Harrison Avenue, Boston, MA, USA, 02118

Website

https://www.hillevax.com

HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.

Executives

Robert Hershberg	director, officer: President and CEO	3005 FIRST AVENUE, SEATTLE WA 98121
Shane Maltbie	officer: Chief Financial Officer	C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Aditya Kohli	director, officer: Chief Operating Officer	C/O PHATHOM PHARMACEUTICALS, INC., 2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE IL 60089
Frazier Life Sciences X, L.p.	10 percent owner	601 UNION STREET, SUITE 3200, TWO UNION SQUARE, SEATTLE WA 98101
Astrid Borkowski	officer: Chief Medical Officer	C/O HILLEVAX, INC., 75 STATE STREET, SUITE 100 - #9995, BOSTON MA 02109
Nanette Cocero	director	C/O HILLEVAX, INC., 75 STATE STREET, SUITE 100, BOSTON MA 02109
Fhmls X, L.l.c.	10 percent owner	601 UNION STREET, SUITE 3200, TWO UNION SQUARE, SEATTLE WA 98101
Gary Dubin	director	C/O HILLEVAX, INC., 75 STATE STREET, SUITE 100 - #9995, BOSTON MA 02109
Jaime Sepulveda	director	C/O HILLEVAX INC., 75 STATE STREET 100 - #9995, BOSTON MA 02109
Takeda Vaccines, Inc.	10 percent owner	75 SIDNEY STREET, CAMBRIDGE MA 02139
Shelley Chu	director	ONE WINTHROP SQUARE, SUITE 400, BOSTON MA 02110
Susan Michele Silbermann	director	C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540
Fhmls X, L.p.	10 percent owner	601 UNION STREET, SUITE 3200, TWO UNION SQUARE, SEATTLE WA 98101
Julie L. Gerberding	director	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
David A Socks	officer: CFO & Chief Business Officer	C/O CADENCE PHARMACEUTICALS, INC., 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130